AIM ImmunoTech (STU:HXB2) Other Long Term Assets : €1.55 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Other Long Term Assets?

AIM ImmunoTech's other long-term assets for the quarter that ended in Mar. 2024 was €1.55 Mil.

AIM ImmunoTech's quarterly other long-term assets declined from Sep. 2023 (€1.97 Mil) to Dec. 2023 (€1.55 Mil) but then increased from Dec. 2023 (€1.55 Mil) to Mar. 2024 (€1.55 Mil).

AIM ImmunoTech's annual other long-term assets declined from Dec. 2021 (€1.17 Mil) to Dec. 2022 (€1.14 Mil) but then increased from Dec. 2022 (€1.14 Mil) to Dec. 2023 (€1.55 Mil).

AIM ImmunoTech Other Long Term Assets Historical Data

The historical data trend for AIM ImmunoTech's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Other Long Term Assets Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

1.70

0.62

1.17

1.14

1.55

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial															1.36	1.65	1.97	1.55	1.55

AIM ImmunoTech Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines